J001 Preliminary results from the first-in-human study of ER2001, an innovative treatment for Huntington’s disease using in vivo self-assembled sirna

体内 疾病 计算机科学 医学 生物 生物技术 内科学
作者
Zhong Pei,Lin Li,Xi Chen,Tengteng Wu,Lishan Lin,Pingyi Xu,Xia Meng
标识
DOI:10.1136/jnnp-2024-ehdn.322
摘要

Background

ER2001 is a genetic circuit (plasmid) encoding both a neuron-targeting rabies virus glycoprotein (RVG) tag and an HTT siRNA. This circuit is able to reprogram liver cells to transcribe and self-assemble HTT siRNA into RVG-tagged exosomes after intravenous administration. The RVG guided HTT siRNA is further delivered through the exosome-circulating system to the cortex and striatum. In the preclinical studies ER2001 lowered mHTT, improved behavioural deficits and ameliorated neuropathologies

Objective

To evaluate the safety and tolerability of ER2001 in patients with early manifest HD including the pharmacokinetics (PK) of ER2001 in plasma and the exposure of ER2001 in cerebrospinal fluid (CSF).

Methods

This open label, single center pilot study evaluates a single dose of ER2001 followed by multiple doses in eligible patients with early manifest HD. A modified 3 plus 3 dose-escalation design is employed with escalating rules set according to the incidence of dose-limiting toxicity (DLT) including assessment of safety, PK, PD and UHDRS. Participants will receive totally 8 intravenous injections of ER2001 and the treatment period of 14 weeks will be followed by an observation phase of 84 days after the last injection. The Biomarkers will be measured to examine the target engagement.

Results

We have enrolled 6 patients and revealed a total of 9 mild-moderate AEs in 2 female patients. None of AEs is related to ER2001. No SAE is present. Lab test indicated that ER2001 could lower CSF NfL level.

Conclusions

The safety review committee (SRC) with accesses to all unblinded data thoroughly reviewed the safety data and concluded that to date no safety signals of concern emerged. (Safety, PK, PD, and clinical outcomes will be updated once available) (ClinicalTrials.gov Identifier: NCT 06024265)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fx完成签到 ,获得积分10
刚刚
zhutu完成签到,获得积分10
刚刚
潇洒的白昼完成签到,获得积分10
刚刚
xyq完成签到 ,获得积分10
1秒前
windli完成签到,获得积分10
1秒前
roywin完成签到,获得积分10
2秒前
隐形的979发布了新的文献求助10
3秒前
sci完成签到 ,获得积分10
4秒前
Linky完成签到 ,获得积分10
4秒前
cq发布了新的文献求助10
4秒前
凶狠的半山完成签到,获得积分10
4秒前
量子猫完成签到 ,获得积分10
5秒前
Lam完成签到,获得积分10
5秒前
刘威发布了新的文献求助10
6秒前
张三完成签到,获得积分10
6秒前
7秒前
Zephyr完成签到 ,获得积分10
8秒前
875259完成签到,获得积分10
8秒前
8秒前
SciGPT的应助被lancerimpp采纳,获得10
9秒前
Dan完成签到,获得积分10
9秒前
wellforever完成签到 ,获得积分10
10秒前
ma完成签到 ,获得积分10
11秒前
我是老大的应助被小暴采纳,获得10
11秒前
凌凌凌完成签到,获得积分10
12秒前
kongzhiqiqi完成签到,获得积分10
12秒前
yyp完成签到,获得积分10
12秒前
12秒前
菜菜完成签到 ,获得积分10
12秒前
14秒前
余香的应助被windli采纳,获得10
16秒前
324完成签到,获得积分10
16秒前
B_lue完成签到 ,获得积分10
17秒前
赵浩宇完成签到,获得积分10
17秒前
资格丘二完成签到,获得积分0
17秒前
英俊的铭的应助被夏傥采纳,获得10
18秒前
19秒前
舒心的冥茗完成签到,获得积分10
19秒前
地瓜完成签到,获得积分10
20秒前
科研通AI6.3的应助被单薄幻梦采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039